Toshiba’s Double-Transmon Coupler Will Realize Faster, More Accurate Superconducting Quantum Computers
15.9.2022 18:23:00 EEST | Business Wire | Press release
Researchers at Toshiba Corporation (TOKYO: 6502) have achieved a breakthrough in quantum computer architecture: the basic design for a double-transmon coupler that will improve the speed and accuracy of quantum computation in tunable couplers. The coupler is a key device in determining the performance of superconducting quantum computers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913006341/en/
Conceptual diagram of a superconducting quantum computer (Graphic: Business Wire)
Tunable couplers in a superconducting quantum computer link two qubits and perform quantum computations by turning on and off the coupling between them. Current technology can turn off the coupling of transmon qubits with close frequencies, but this is prone to crosstalk errors that occur on one of the qubits when the other qubit is irradiated with electromagnetic waves for control. In addition, current technology cannot completely turn off coupling for qubits with significantly different frequencies, resulting in errors due to residual coupling.
Toshiba has recently devised a double-transmon coupler that can completely turn on and off the coupling between qubits with significantly different frequencies. Completely turning on enables high-speed quantum computations with strong coupling, while completely turning off eliminates residual coupling, which improves quantum computation speeds and accuracy. Simulations with the new technology have shown it realizes two-qubit gates, basic operations in quantum computation, with an accuracy of 99.99% and a processing time of only 24 ns.
Toshiba’s double-transmon coupler can be applied to fixed-frequency transmon qubits, realizing high stability and ease of design. It is the first to realize coupling between fixed-frequency transmon qubits with significantly different frequencies that can be completely switched on and off, and to deliver a high-speed, accurate two-qubit gate.
The technology is expected to advance the realization of higher-performance quantum computers that will contribute in such areas as the achievement of carbon neutrality and the development of new drugs. Details of the technology were published in the United States on September 15 in the Physical Review Applied, a journal of the American Physical Society (https://doi.org/10.1103/PhysRevApplied.18.034038).
The full release: https://www.global.toshiba/ww/technology/corporate/rdc/rd/topics/22/2209-01.html
About Toshiba
Toshiba Corporation leads a global group of companies that combines knowledge and capabilities from over 140 years of experience in a wide range of businesses—from energy and social infrastructure to electronic devices—with world-class capabilities in information processing, digital and AI technologies. These distinctive strengths support Toshiba’s continued evolution toward becoming an Infrastructure Services Company that promotes data utilization and digitization, and one of the world’s leading cyber-physical-systems technology companies. Guided by the Basic Commitment of the Toshiba Group, “Committed to People, Committed to the Future,” Toshiba contributes to society’s positive development with services and solutions that lead to a better world. The Group and its 120,000 employees worldwide secured annual sales of 3.3 trillion yen (US$27.4 billion) in fiscal year 2021.
Find out more about Toshiba at www.global.toshiba/ww/outline/corporate.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006341/en/
Contact information
Toshiba Corporation
Corporate Communications Div.
Tatsuro Oishi / Naoko Oura
media.relations@toshiba.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom